Catalog No.
Product Name
Application
Product Information
Citations
- Cardiogenol C is a diaminopyrimidine compound that induces the differentiation of MHC- (myosin heavy chain) positive cardiomyocytes from embryonic stem cells with an EC50 value of 0.1 uM. Cardiogenol C upregulates cardiac markers and induces cardiac functional properties in lineage-committed progenitor cells.
- OVA Peptide(257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
- OVA 55-62 is a fragmented peptide of OVA (ovalbumin) antigen and can bind to the mouse MHC class I molecule, H2-Kb.
-
NSUN2 inhibitor
MY-1B is a covalent inhibitor of the RNA methyltransferase NSUN2 (IC50: 1.3 μM), stereoselectively targeting active-site cysteine residues (C271). It also covalently binds to PSME1, disrupting the proteasome regulatory complex and downregulating specific MHC-I subtype presentation. -
Anti-Inflammatory Agent
LM-021 is a coumarin-chalcone derivative that functions as an anti-inflammatory agent through its ability to suppress the production of nitric oxide (NO), IL-1β, IL-6, and TNF-α, along with the expression of CD68 antigen and histocompatibility-2 (MHCII). Additionally, it attenuates caspase 1 activity, lactate dehydrogenase release, and levels of reactive oxygen species (ROS). This compound is suitable for applications in neurological research, highlighting its potential in studies related to neuroinflammation and related pathways. -
B3GAT3 Inhibitor
TMLB-C16 is a selective B3GAT3 inhibitor with a dissociation constant (KD) of 3.962 μM. This compound effectively suppresses cell proliferation and migration while inducing cell cycle arrest and apoptosis in hepatocellular carcinoma cell lines MHCC-97H and HCCLM3, exhibiting IC50 values of 6.53 μM and 6.22 μM, respectively. In vivo studies demonstrate that TMLB-C16 inhibits tumor growth in MHCC-97H and HCCLM3 xenograft models without significant toxicity. TMLB-C16 is a valuable tool for research in hepatocellular carcinoma. -
STING Agonist
M04 is a potent agonist of stimulator of interferon genes (STING), specifically activating the wild-type human STING in HEK293T cells while demonstrating no efficacy with the HAQ STING variant or in mouse RAW 264.7 cells. It effectively induces the expression of pro-inflammatory cytokines such as TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 enhances dendritic cell maturation, promoting the expression of MHC class II (HLA-DR) and co-stimulatory molecules (CD40, CD80, CD86), thereby boosting T cell activation. This reagent is valuable for research in inflammatory immune diseases. -
Anti-inflammatory Agent
MDL 201112 is a carbocyclic nucleoside functioning as an anti-inflammatory agent. It effectively reduces TNF-α production and inhibits the expression of MHC class II Ia+ antigens. This compound is valuable for research applications focused on inflammation and immunology, providing insights into the mechanisms underlying these biological processes. -
TNF Receptor
SYLQDSVPDSFQD is an anchor-modified peptide designed for high-affinity binding to the TNF receptor, specifically DR4. This DR4-restricted MHC class II peptide is utilized in research for studying immune responses and the modulation of TNF-mediated signaling pathways. Its enhanced binding properties make it a valuable tool for investigating therapeutic strategies in inflammation and cancer research. -
DR4 Ligand
SC-67655 is a potent pentapeptide ligand targeting the MHC class II haplotype DR4 (DR4 Dw4 or DRB 1*0401) with an IC50 of 50 nM. This stable compound is suitable for research applications focusing on autoimmune diseases, facilitating the exploration of immune responses and potential therapeutic interventions. -
ADAM-17 Inhibitor
ZLDI-8 is an inhibitor of the metalloproteinase enzyme ADAM-17, targeting the cleavage of Notch protein. This compound effectively reduces the expression of proteins associated with pro-survival pathways and epithelial-mesenchymal transition (EMT). Additionally, ZLDI-8 functions as a competitive and irreversible inhibitor of the tyrosine phosphatase Lyp, exhibiting an IC50 of 31.6 μM and a Ki of 26.22 μM. Notably, ZLDI-8 demonstrates potent growth inhibition of MHCC97-H cells with an IC50 of 5.32 μM, making it valuable for research into cellular signaling and cancer biology. -
JAK2 Inhibitor
Tkip is a selective inhibitor of JAK2, targeting the JAK2 autophosphorylation site. It effectively inhibits JAK2 autophosphorylation and the phosphorylation of the IFN-γ receptor subunit IFNGR-1, thereby reducing the antiviral effects of IFN-γ and downregulating MHC Class I molecule expression. Tkip is a valuable tool for investigating the IFN-γ signaling pathway and its implications in various biological processes. -
EGFRvIII Epitope
EGFRvIII peptide is a synthetic epitope derived from the EGFRvIII variant, specifically designed to bind to MHC I molecules. This peptide is known to induce apoptosis and elicit targeted immune responses against glioblastoma, particularly when used in conjunction with Flagellin B. It is a valuable tool for research in cancer immunotherapy and the development of personalized medicine approaches for glioblastoma treatment. -
TLR2 Agonist
Pam2Cys is a TLR2 agonist that acts as an immunostimulant by binding to TLR2, activating dendritic cells, and initiating the TLR2-dependent NF-κB signaling pathway. This compound promotes dendritic cell maturation through the upregulation of MHC II molecules, enhances innate immune signaling, and drives pro-inflammatory responses, including the release of IL-12 and other cytokines. Additionally, Pam2Cys serves as a lipid moiety in synthetic lipopeptide vaccines, boosting immunogenicity, while selectively inducing pro-inflammatory macrophage activation. Research applications include studies on tuberculosis and influenza A virus infections, as it effectively recruits immune cells and mitigates infection-related symptoms without compromising adaptive immunity. -
Toll-like Receptor (TLR) Ligand
Ste2Cys is a diacylglycerol cysteine-type lipid molecule that serves as a ligand for Toll-like Receptor 2 (TLR2). It activates the NF-κB signaling pathway, leading to the upregulation of MHC II class molecules on the surface of mouse bone marrow-derived dendritic cells. This compound is valuable for research into the development of immunologic vaccines and enhancing immune responses. -
CSF1R/Mer/Axl Inhibitor
Adrixetinib is a potent triple inhibitor targeting CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM respectively. This compound serves as an effective immune modulator by remodeling the tumor microenvironment, enhancing the presence of M1 macrophages and CD8⁺ T cells while reducing M2 macrophages and myeloid-derived suppressor cells (MDSCs). Additionally, Adrixetinib increases the expression of MHC class I and E-cadherin in tumor cells, demonstrating significant antitumor efficacy in syngeneic mouse models. It is relevant for research involving breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma. -
PIKfyve Inhibitor
AS2677131 is a potent and orally active inhibitor of PIKfyve, targeting the PIKfyve-c-Rel signaling pathway. It effectively inhibits the production of pro-inflammatory cytokines, including IL-12p40, IL-6, and IL-1β, by selectively blocking the DNA-binding activity of c-Rel to their respective promoters. Additionally, AS2677131 reduces MHC class II expression on B cells. This compound is valuable for research in the fields of inflammation and immunology, particularly in studies related to arthritis. -
ULK1/ULK2 Inhibitor
SBP-5147 is a potent inhibitor of ULK1 and ULK2, exhibiting an IC50 of 2 nM for ULK1 and 53 nM for ULK2. This compound effectively inhibits the phosphorylation of Beclin-1 and Vps34, reduces autophagic flux, and downregulates the expression of key autophagy-related proteins ATG13 and ATG101. Additionally, SBP-5147 enhances MHC-I expression, induces caspase-dependent apoptosis, and decreases the viability of non-small cell lung cancer cells. Its mechanism of action makes SBP-5147 a valuable tool for research in non-small cell lung cancer and autophagy modulation. -
CATS Inhibitor
Z-Val-Val-Nle-diazomethylketone is a selective inhibitor of cathepsin S (CATS). This compound effectively reduces the IFNg-induced upregulation of MHCII molecules, specifically HLA-DR and Ii-p33/35, while promoting an increase in the Ii-p10 protein level. It is valuable for research into dermatological conditions such as psoriasis, atopic dermatitis, and actinic keratosis. -
Autotaxin Inhibitor
MHC02181 is a potent inhibitor of Autotaxin (ATX), demonstrating an IC50 value of 9.41 μM. By inhibiting ATX, it plays a critical role in modulating lysophosphatidic acid (LPA) production, which is involved in various physiological and pathological processes. This reagent is valuable for research applications focused on cancer progression, fibrosis, and other ATX-mediated diseases. -
Autotaxin Inhibitor
MHC00188 is an allosteric inhibitor of Autotaxin (ATX) with an IC50 of 2.53 μM. This compound modulates ATX activity, which plays a critical role in the production of lysophosphatidic acid (LPA), a signaling lipid involved in various physiological processes. MHC00188 is useful for research into cancer biology, inflammation, and other conditions related to aberrant LPA signaling. -
WNT7A Inhibitor/Photosensitizer
WNT7A-IN-1 sodium is a selective inhibitor of WNT7A that disrupts the interaction between WNT7A and its receptor FZD5, leading to enhanced expression of MHC-I. This reagent is known to significantly increase levels of MHC-I and phosphorylated p65 while decreasing active β-catenin expression. Additionally, WNT7A-IN-1 sodium acts as a photosensitizer in the green spectral region, making it suitable for applications in photodynamic therapy and immunological studies. -
WNT7A Inhibitor/Photosensitizer
WNT7A-IN-1 is a WNT7A inhibitor that disrupts the interaction between WNT7A and its receptor FZD5, leading to the upregulation of MHC-I expression. This compound enhances the expression of MHC-I and phosphorylated p65 while decreasing the levels of active β-catenin. Additionally, WNT7A-IN-1 serves as a photosensitizer in the green spectral region, making it valuable for research in cancer immunotherapy and photodynamic therapy applications. -
LCMV Glycoprotein Peptides Frgment
LCMV gp33-41 is a peptide fragment derived from the glycoprotein of the lymphocytic choriomeningitis virus (LCMV), specifically a carboxyl-extended 9-amino acid sequence. This peptide is restricted by MHC class I H-2Db molecules, facilitating its recognition and presentation to cytotoxic T lymphocytes. LCMV gp33-41 is pivotal for immunological research applications, including the study of T cell responses and viral pathogenesis. -
Exotoxin
LLO (91-99), a peptide derived from the exotoxin listeriolysin O, acts as a class I MHC-restricted T-cell epitope. This peptide is processed by antigen-presenting cells, binding to MHC class I molecules to elicit cytotoxic T lymphocyte (CTL) responses. LLO (91-99) is instrumental in research focused on Listeria infections, such as listeriosis, by facilitating the clearance of Listeria from infected cells. -
Immunoactive Peptide
ESAT6 Epitope is an immunoactive peptide derived from the early secreted antigen target gene 6 (ESAT6), specifically designed to bind with high affinity to major histocompatibility complex (MHC) class I, exhibiting an IC50 of 180 nM. This epitope plays a crucial role in enhancing BCG-induced cellular immunity against Mycobacterium tuberculosis. It is valuable in studies focused on T cell-mediated immune responses and tuberculosis vaccine development. -
PAD4 Inhibitor
GSK484 is a selective inhibitor of peptidylarginine deiminase 4 (PAD4), effectively blocking the enzyme's catalytic activity to inhibit protein citrullination and neutrophil extracellular trap (NET) formation. This compound demonstrates anti-inflammatory properties by reducing histone H3 production, modulating MHC-I expression, and inhibiting CD8+ T cell activation and proliferation. Research applications include studies on rheumatoid arthritis, sickle cell disease, myocardial ischemia-reperfusion injury, and colitis, as well as investigations into intestinal microbial homeostasis and ferroptosis-related dysbiosis. -
HLA-A*0201 Stabilizer
ELTLGEFLKL is a survivin-derived peptide that functions as a stabilizer of HLA-A*0201. This peptide demonstrates significant enhancement of HLA-A*0201 stability, making it a valuable tool in the study of tumor immunotherapy. ELTLGEFLKL can be employed in research focused on optimizing immune responses against cancer through modulation of peptide-MHC interactions. -
Tumor Suppressor Peptide
p53 (232-240) is a peptide derived from the 232-240 amino acid sequence of the human tumor suppressor protein p53. This peptide enhances binding affinity to the Major Histocompatibility Complex (MHC), thus increasing its immunogenicity and bolstering the immune system's response to tumor antigens. p53 (232-240) is valuable in cancer vaccine development and studies focused on tumor cell recognition and clearance by immune cells. -
RSV Epitope
Fusion Glycoprotein (92-106) is a peptide derived from the fusion protein of respiratory syncytial virus (RSV). It serves as a MHC class I-restricted cytotoxic T lymphocyte (CTL) epitope, with all 15 amino acids essential for optimal recognition by CTLs. This reagent is valuable for research in virology and immunology, particularly in the evaluation of T cell responses to RSV and the development of vaccines targeting RSV. -
HPV Epitope Peptides Fragment
Human Papillomavirus (HPV) E7 protein (49-57) is a fragment of the E7 protein, specifically the epitope spanning amino acid residues 49 to 57, which is restricted by the H-2d MHC class I molecule. This peptide is vital for studying HPV-induced tumorigenesis and immune response mechanisms. It is commonly utilized in research applications focusing on HPV vaccination, T cell recognition, and the understanding of viral oncogenesis. -
Bioactive Peptide
Influenza NP (311-325) is a bioactive peptide derived from the nucleoprotein (NP) of the influenza virus, acting as an MHC class II restricted epitope to stimulate host immune responses. This peptide is known for its ability to induce substantial interferon gamma (IFN-γ) production while avoiding activation of CD8 T cells in murine models. Its unique properties make Influenza NP (311-325) a valuable tool for research in immunology and vaccine development. -
HIV-1 Nef Binder, IKZF1 Modulator
FC-14369 is a PROTAC degrader that selectively targets the HIV-1 Nef protein, exhibiting a DC50 value of 160 nM. By engaging both Nef and the Cereblon E3 ubiquitin ligase, FC-14369 facilitates the ubiquitination and subsequent proteasomal degradation of Nef, leading to the restoration of CD4 and MHC-I expression on the cell surface and effectively inhibiting HIV-1 replication. This compound is valuable for research focused on HIV infection and AIDS, advancing understanding of therapeutic strategies in viral infections. -
PROTAC Degrader
FC-14367 is a PROTAC degrader that selectively targets the HIV-1 Nef protein. It facilitates the formation of a ternary complex by simultaneously binding to Nef and Cereblon E3 ubiquitin ligase, leading to the ubiquitination and subsequent proteasomal degradation of Nef. This process restores the surface expression of CD4 and MHC-I molecules while effectively inhibiting HIV-1 replication. FC-14367 is valuable for research focused on HIV infection and AIDS pathogenesis. -
HBsAg Peptide
HBV Seq2 aa:28-39 is a peptide derived from Hepatitis B Surface Antigen (HBsAg) that specifically interacts with major histocompatibility complex (MHC) class I molecules. This interaction is crucial for the activation of CD8+ T cells, making it an important tool for studying immune responses to HBV infection. It is widely used in vaccine research and T cell epitope mapping to enhance understanding of viral pathogenesis and immune evasion mechanisms. -
CETP Inhibitor/CB1 Agonist
BI-5756 is a selective CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. It promotes a significant increase in HDL-C levels while reducing LDL-C levels, thereby improving lipid profiles. Additionally, BI-5756 enhances the function of regulatory T cells and preserves T cell-mediated anti-tumor activity, exhibiting direct anti-proliferative effects on tumor cells. This compound also upregulates the expression of MHC I, MHC II, and CD80 on tumor cells and demonstrates protective effects in graft-versus-host disease. BI-5756 is applicable in research related to oncology, graft-versus-host disease, and metabolic disorders. -
Octamer Peptide
OVA Peptide (257-264) is an octameric peptide epitope derived from ovalbumin that is specifically presented by the class I major histocompatibility complex (MHC) molecule H-2Kb. This peptide is crucial for T cell recognition and activation in immunological studies. It has applications in the development of immunotherapies, vaccine research, and studies focusing on T cell responses. -
Immunodominant Antigen
AH1 is an MHC class I-restricted tumor-specific antigenic peptide that engages the murine MHC class I molecule Ld. Derived from the envelope protein (gp70) of the endogenous ecotropic murine leukemia virus (MuLV), AH1 serves as an immunodominant CTL epitope in CT26 colon carcinoma and TS/A murine mammary adenocarcinoma. The specific CTLs that recognize AH1 can effectively mediate cytotoxicity, leading to tumor cell killing and rejection. This peptide is valuable for research applications targeting tumor immunology and the development of cancer immunotherapies. -
Kb-restricted Epitope
KSPWFTTL is an immunodominant Kb-restricted epitope derived from the p15E transmembrane protein. This peptide effectively enhances the susceptibility of tumor lines to cytotoxic T lymphocytes specific for anti-AKR/Gross MuLV. KSPWFTTL is valuable for research applications focused on tumor immunology and T cell-mediated responses. -
EAE Inducer
MOG (35-55), human is a peptide derived from myelin oligodendrocyte glycoprotein, primarily functioning as an EAE inducer. This peptide possesses unique immunogenic properties as it binds to H-2b class II MHC and is recognized by T cells, facilitating the study of autoimmune responses in the central nervous system. Although it is associated with minimal clinical signs of experimental autoimmune encephalomyelitis compared to its rodent counterpart, mMOG (35-55), it is crucial for understanding the mechanisms of demyelination and neuroinflammation. Research applications include model development for multiple sclerosis and the exploration of T cell activation in autoimmune diseases. -
Glycol
1,10-Decanediol is a diol compound that interacts with α-ketoglutarate (aKG) to form polymeric microparticles (paKG MPs) for the controlled release of aKG, facilitating immunosuppressive responses. These microparticles can engage dendritic cells (DCs), leading to decreased glycolysis and mitochondrial respiration, which subsequently modulate MHC-II and CD86 expression in DCs and influence the proportions of regulatory T cells (Tregs) and various T-helper cell subsets in vitro. This compound serves as a valuable tool in immunometabolism research and functions as a surfactant/stabilizer in nanomaterial synthesis. -
Antigen Peptide
OVA(250-264) is an antigenic peptide derived from ovalbumin, targeting the class I MHC molecule H-2Kb. This peptide has been shown to significantly enhance the generation and infiltration of antigen-specific CD8+ T cells when used in conjunction with αMSLN (anti-MSLN antibody), thus improving antitumor efficacy in orthotopic models of pancreatic cancer. OVA(250-264) serves as a valuable tool for the development of neoantigen vaccines in immunotherapy research focused on pancreatic cancer. -
HLA-DR Binding Epitope
PADRE peptide is a pan-HLA-DR binding epitope that functions as an immunostimulant by binding to the peptide-binding groove of MHC class II molecules, facilitating the activation of CD4+ T cells. This leads to enhanced anti-tumor immune responses, inhibition of tumor growth, and prolonged survival in model systems. PADRE peptide is effective in increasing the frequency of E7-specific CD8+ T cells and improving therapeutic outcomes when combined with E7 peptide-based vaccines and poly (I:C). It is suitable for research applications in various tumor models, including melanoma, glioblastoma, and cervical cancer. -
MR1 Ligand
DB28 is an innovative MR1 ligand that functions by competitively inhibiting the activation of mucosal-associated invariant T (MAIT) cells through its interaction with MR1. Additionally, DB28 reduces the cell surface expression of MR1, making it a valuable tool for studies of MAIT cell biology and immune modulation. This compound is applicable in research focused on immune responses and potential therapeutic interventions targeting MR1-related pathways. -
GAD65 Residue
GAD65 (206-220) is a peptide derived from glutamic acid decarboxylase (GAD) 65, specifically corresponding to residues 206-220. It plays a pivotal role in immune recognition, as it is presented to T cells by I-Ag7 MHC class II molecules. This peptide is significant for research related to type I diabetes mellitus, where it is targeted by self-reactive T cells, aiding in the understanding of autoimmune responses. -
CD8-related Self-antigenic Epitope
Myelin Oligodendrocyte Glycoprotein (40-54) serves as a CD8-related self-antigenic epitope derived from the myelin oligodendrocyte glycoprotein (MOG) and is presented in association with H-2Db. This peptide is crucial for studying autoimmune responses in experimental models, particularly in the context of multiple sclerosis research. It can be utilized in assays to investigate T cell activation and epitope-specific immune responses in both rat and mouse models. -
T Cell Inducing Determinant
Hemoglobin (64-76) serves as a T cell inducing determinant that interacts with two distinct MHC class II molecules, utilizing different registers and lengths. This interaction is crucial for T cell activation and modulation, making it an important reagent for immunological research. Its biological activity facilitates studies on T cell responses, antigen presentation, and the development of therapeutic strategies in autoimmune and infectious diseases. -
Nucleoprotein Peptide
H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide specifically derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). This peptide interacts with MHC class I molecules, facilitating the presentation to CD8+ T cells and promoting the activation of cytotoxic T lymphocytes (CTLs). It is particularly valuable in research focused on CTL vaccine development for infectious diseases, including Ebola virus, enhancing understanding of immune responses in viral infections. -
HLA-E Ligand
VMAPRTLFL is a 9-mer peptide that acts as a ligand for HLA-E, derived from the signal peptide of HLA-G. This peptide is essential for modulating the activity of adaptive natural killer (NK) cells, enhancing their proliferation, antibody-dependent cellular cytotoxicity (ADCC), and interferon-gamma (IFN-γ) release through upregulation of CD25 expression. VMAPRTLFL is valuable for research into human cytomegalovirus (HCMV) infection, transplant rejection, and mechanisms underlying pregnancy immunity.
